CD8+ T cells use TRAIL to restrict west nile virus pathogenesis by controlling infection in neurons

Journal of Virology

Volumn 86, Issue 17, 2012, Pages 8937-8948

  Shrestha, Bimmi ^a   Pinto, Amelia K ^a   Green, Sharone ^b   Bosch, Irene ^c   Diamond, Michael S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD45 ANTIGEN; DEATH RECEPTOR 5; FAS LIGAND; GRANZYME B; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BRAIN INFECTION; CD8+ T LYMPHOCYTE; CELL MIGRATION; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE PREDISPOSITION; FLAVIVIRUS INFECTION; INFECTION CONTROL; INFECTION PREVENTION; INTRACELLULAR SIGNALING; LYMPHOCYTE FUNCTION; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SPINAL CORD INFECTION; SURVIVAL RATE; TISSUE DISTRIBUTION; VIRAL CLEARANCE; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS LOAD; VIRUS REPLICATION; VIRUS VIRULENCE; WEST NILE FLAVIVIRUS; WILD TYPE;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, VIRAL; BRAIN; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURONS; SPINAL CORD; TNF-RELATED APOPTOSIS-INDUCING LIGAND; VIRAL LOAD; WEST NILE FEVER; WEST NILE VIRUS;

DENGUE VIRUS; FLAVIVIRUS; MUS; WEST NILE VIRUS;

EID: 84866144157     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00673-12     Document Type: Article

References (41)

1. Beraza N, et al. 2009. Hepatocyte-specific NEMO deletion promotes NK/NKT cell- and TRAIL-dependent liver damage. J. Exp. Med. 206: 1727-1737.
2. Brincks EL, et al. 2011. The magnitude of the T cell response to a clinically significant dose of influenza virus is regulated by TRAIL. J. Immunol. 187:4581-4588.
3. Brincks EL, Katewa A, Kucaba TA, Griffith TS, Legge KL. 2008. CD8 T cells utilize TRAIL to control influenza virus infection. J. Immunol. 181: 4918-4925.
4. Busch MP, et al. 2006. West Nile virus infections projected from blood donor screening data, United States, 2003. Emerg. Infect. Dis. 12:395-402.
5. Daffis S, Samuel MA, Keller BC, Gale M, Jr, Diamond MS. 2007. Cell-specific IRF-3 responses protect against West Nile virus infection by interferon-dependent and independent mechanisms. PLoS Pathog. 3:e106. doi:10.1371/journal.ppat.0030106.
6. Daffis S, et al. 2008. Interferon regulatory factor IRF-7 induces the antiviral alpha interferon response and protects against lethal West Nile virus infection. J. Virol. 82:8465-8475.
7. Diamond MS, Mehlhop E, Oliphant T, Samuel MA. 2009. The host immunologic response to West Nile encephalitis virus. Front. Biosci. 14:3024-3034.
8. Diamond MS, Shrestha B, Marri A, Mahan D, Engle M. 2003. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J. Virol. 77:2578-2586.
9. Diehl GE, et al. 2004. TRAIL-R as a negative regulator of innate immune cell responses. Immunity 21:877-889.
10. Ebel GD, Carricaburu J, Young D, Bernard KA, Kramer LD. 2004. Genetic and phenotypic variation of West Nile virus in New York, 2002-2003. Am. J. Trop. Med. Hyg. 71:493-500.
11. Glass WG, et al. 2006. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J. Exp. Med. 203:35-40.
12. Hoffmann O, et al. 2007. TRAIL limits excessive host immune responses in bacterial meningitis. J. Clin. Invest. 117:2004-2013.
13. Hu WH, Johnson H, Shu HB. 1999. Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways. J. Biol. Chem. 274:30603-30610.
14. Indraccolo S, et al. 2007. Identification of genes selectively regulated by IFNs in endothelial cells. J. Immunol. 178:1122-1135.
15. Ishikawa E, Nakazawa M, Yoshinari M, Minami M. 2005. Role of tumor necrosis factor-related apoptosis-inducing ligand in immune response to influenza virus infection in mice. J. Virol. 79:7658-7663.
16. Kotelkin A, Prikhod'ko EA, Cohen JI, Collins PL, Bukreyev A. 2003. Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J. Virol. 77: 9156-9172.
17. Lanteri MC, et al. 2009. Tregs control the development of symptomatic West Nile virus infection in humans and mice. J. Clin. Invest. 119:3266-3277.
18. Lim JK, et al. 2008. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a metaanalysis of 4 cohorts in the US epidemic. J. Infect. Dis. 197:262-265.
19. Lim JK, et al. 2010. CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. J. Infect. Dis. 201:178-185.
20. Lin Y, et al. 2000. The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Mol. Cell. Biol. 20:6638-6645.
21. Mehlhop E, Diamond MS. 2006. Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J. Exp. Med. 203:1371-1381.
22. Merino D, et al. 2006. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol. Cell. Biol. 26:7046-7055.
23. Micheau O. 2003. Cellular FLICE-inhibitory protein: an attractive therapeutic target? Expert Opin. Ther. Targets 7:559-573.
24. Murray K, et al. 2006. Risk factors for encephalitis and death from West Nile virus infection. Epidemiol. Infect. 134:1325-1332.
25. Petersen LR, Marfin AA, Gubler DJ. 2003. West Nile virus. JAMA 290: 524-528.
26. Rigaud S, et al. 2006. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 444:110-114.
27. Samuel MA, Diamond MS. 2006. Pathogenesis of West Nile virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J. Virol. 80:9349-9360.
28. Samuel MA, Diamond MS. 2005. Type I IFN protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J. Virol. 79:13350-13361.
29. Sato K, et al. 2001. Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur. J. Immunol. 31:3138-3146.
30. Secchiero P, et al. 2005. TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood 105:3413-3419.
31. Sedger LM, et al. 1999. IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J. Immunol. 163:920-926.
32. Sejvar JJ, et al. 2006. West Nile virus-associated flaccid paralysis outcome. Emerg. Infect. Dis. 12:514-516.
33. Shepard BD, et al. 2008. Beneficial effect of TRAIL on HIV burden, without detectable immune consequences. PLoS One 3:e3096. doi: 10.1371/journal.pone.0003096.
34. + T cell-mediated control of West Nile virus infection in the central nervous system. J. Virol. 81:11749-11757.
35. + T cells in the control of West Nile virus infection. J. Virol. 78:8312-8321.
36. + T cells to vaccine immunity against West Nile encephalitis virus. Vaccine 26:2020-2033.
37. + T cells require perforin to clear West Nile virus from infected neurons. J. Virol. 80:119-129.
38. Shrestha B, Zhang B, Purtha WE, Klein RS, Diamond MS. 2008. Tumor necrosis factor alpha protects against lethal West Nile virus infection by promoting trafficking of mononuclear leukocytes into the central nervous system. J. Virol. 82:8956-8964.
39. + T cells mediate recovery and immunopathology in West Nile virus encephalitis. J. Virol. 77:13323-13334.
40. Warke RV, et al. 2008. TRAIL is a novel antiviral protein against dengue virus. J. Virol. 82:555-564.
41. Zamai L, et al. 1998. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J. Exp. Med. 188:2375-2380.